In this issue:
- Melanoma shifts in NZ
- Neoadjuvant pembrolizumab- dabrafenib-trametinib in BRAFV600-mutated resectable melanoma
- Managing melanocytic lesions with peripheral globules according to dysplasia grade
- 10-year outcomes with nivolumab + ipilimumab in advanced melanoma
- Increasing melanoma incidence with unchanged mortality
- Fianlimab + cemiplimab in advanced melanoma
- Anxiety/depression in cutaneous malignant melanoma
- Adjuvant pembrolizumab in resected stage III melanoma
- Melanoma among patients with congenital melanocytic naevi
- Real-world NZ outcomes of immunotherapy for melanoma brain metastases
Please login below to download this issue (PDF)